Both responder and remitter patients experienced a statistically significant longer time to relapse with esketamine compared to the placebo
Shyam Patel, PharmD
FDA approves lofexidine for opioid withdrawal symptoms.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.